Search

This is a protocol for a systematic map of studies that have examined the impacts of natural disturbances on soil fauna in forest ecosystems. The systematic map aims to characterise these studies, identify opportunities for future quantitative synthesis, and identify knowledge gaps that warrant further primary studies.

This is a protocol for a systematic map of studies that have examined the impacts of natural disturbances on soil fauna in forest ecosystems. The systematic map aims to characterise these studies, identify opportunities for future quantitative synthesis, and identify knowledge gaps that warrant further primary studies.

This work is a collaboration between BioRISC (the Biosecurity Research Initiative at St Catharine’s College, Cambridge), Conservation Evidence based in the Department of Zoology, University of Cambridge and the Centre for the Study of Existential Risk. It was created by documenting our experience of options, consulting guidance, contacting people working in different countries to explore the range of options and crowd-sourcing ideas through social media. We welcome suggestions for options missed (especially those implemented outside of the UK), innovations for novel options or means of improving existing options. Please contact biorisc@caths.cam.ac.uk. You can also view the list of options on the BioRISC website (https://covid-19.biorisc.com/) or customise the list yourself using this app we developed (https://alecchristie888.shinyapps.io/Covid_19_options/).

This is a protocol for an umbrella review to summarise, explore, and appraise the results of existing syntheses of the impacts of natural disturbances on soil properties in forest ecosystems.

This article is part of the Proceedings of the 6th Annual International Cycling Safety Conference held in Davis, California, USA on September 20th through 23rd in the year 2017.Paper ID: 65

Considerable scope exists to vary the physical and chemical properties of nanoparticles, with subsequent impact on biological interactions; however, no accelerated process to access large nanoparticle material space is currently available, hampering the development of new nanomedicines. In particular, no clinically available nanotherapies exist for HIV populations and conventional paediatric HIV medicines are poorly available; one current paediatric formulation utilizes high ethanol concentrations to solubilize lopinavir, a poorly soluble antiretroviral. Here we apply accelerated nanomedicine discovery to generate a potential aqueous paediatric HIV nanotherapy, with clinical translation and regulatory approval for human evaluation. Our rapid small-scale screening approach yields large libraries of solid drug nanoparticles (160 individual components) targeting oral dose. Screening uses 1 mg of drug compound per library member and iterative pharmacological and chemical evaluation establishes potential candidates for progression through to clinical manufacture. The wide applicability of our strategy has implications for multiple therapy development programmes., Nanomedicine efficacy in a clinical setting depends on the pharmacological properties of the therapeutic nanoparticles. Here, the authors exemplify an accelerated translational strategy from small-scale screening to clinical scale-up for an orally-dosed aqueous paediatric HIV nanomedicine.